Akt phosphorylation at Ser473 predicts benefit of paclitaxel chemotherapy in node-positive breast cancer. [electronic resource]
Producer: 20100706Description: 2974-81 p. digitalISSN:- 1527-7755
- Adenocarcinoma -- drug therapy
- Antineoplastic Combined Chemotherapy Protocols -- therapeutic use
- Breast Neoplasms -- drug therapy
- Chemotherapy, Adjuvant
- Cyclophosphamide -- administration & dosage
- Doxorubicin -- administration & dosage
- Female
- Follow-Up Studies
- Humans
- Immunoenzyme Techniques
- Lymph Nodes -- metabolism
- Lymphatic Metastasis
- Middle Aged
- Neoplasm Staging
- Paclitaxel -- administration & dosage
- Phosphorylation
- Proto-Oncogene Proteins c-akt -- metabolism
- Receptor, ErbB-2 -- metabolism
- Receptors, Estrogen -- metabolism
- Receptors, Progesterone -- metabolism
- Serine -- chemistry
- Tissue Array Analysis
- Treatment Outcome
No physical items for this record
Publication Type: Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural
There are no comments on this title.
Log in to your account to post a comment.